In over 90% of MPN, a driver mutation in the genes encoding JAK2, CALR or MPL results in constitutive activation of the MPL‐JAK–STAT signalling pathway.4, 5, 6. The gene discussed is MPL; the disease is myeloproliferative neoplasm.